Outpost Bio is decoding the hidden interactions that drive human biology. The company combines high-throughput assays of human-derived microbial communities with machine learning to build frontier models that reveal causal pathways - not just correlations. Headquartered in Boston and London, the company enables any partner developing molecules that go into or onto humans to predict microbe-mediated metabolism, toxicity, and response - making human microbiology computable for the first time.
- Life Sciences
- London, United Kingdom
- £2.6m
- outpost.bio
- Update Information
More venture news
- 29 Jul 2026

QureightQureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease
Series BLife Sciences - 7 Jul 2026

Healome TherapeuticsHealome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease
SeedLife Sciences - 6 Jul 2026

Revolver TherapeuticsRevolver Therapeutics raises £600k in funding led by QantX to develop peptides that shut down cancer-driving proteins
EquityLife Sciences
